secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001398733-25-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q2 net loss $13.5M; FDA accepts Anaphylm NDA, PDUFA Jan 31, 2026
--------------------------------------------------------------------------

- Total revenue $10.0M, down 50% YoY; excluding one-time deferred revenue, up 3% to $10.0M.
- Net loss $13.5M ($0.14/sh) vs $2.7M loss ($0.03) in Q2 2024; adjusted EBITDA loss $9.3M.
- Cash $60.5M at June 30; FY2025 guidance: revenue $44-50M, adjusted EBITDA loss $47-51M.
- FDA accepted Anaphylm NDA; PDUFA date Jan 31, 2026; Q1 2026 launch planned if approved.
- Anaphylm global expansion to Canada and EU; AQST-108 IND for alopecia areata expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/0001398733-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/aqst-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001398733-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer